A larger debt and higher interest rates would cancel out the boost from keeping individual taxes lower, the nonpartisan Congressional Budget Office found.
Category: Presidential Election of 2024
-
Bill Clinton Defends the Hunter Biden Pardon, but Suggests It Was Mishandled
The former president, speaking at the DealBook Summit, suggested that he understood the move but that he wished President Biden “hadn’t said he wasn’t going to do it.”
-
Trump Picks Paul Atkins to Run the S.E.C.
Mr. Atkins, a pro-business conservative, would likely take a lighter regulatory approach than the current chair of the Securities and Exchange Commission.
-
Ken Griffin, Top Republican Donor, Says He Voted for Trump
Mr. Griffin, who had previously derided Donald J. Trump as a “three-time loser,” said he voted for the president-elect.
-
What to Expect at Today’s DealBook Summit: Full Speaker Lineup
Sam Altman, Jerome Powell, Jeff Bezos, Bill Clinton, the podcaster Alex Cooper, Ken Griffin, Prince Harry, and Serena Williams are among the big names speaking.
-
G.M. Will Sell Stake in EV Battery Plant to LG
LG Energy Solution will now solely own a factory in Michigan that it had planned to operate through a joint venture with General Motors.
-
Stocks Resume Post-Election Rise
With Friday’s gains included, November was the best month in a year for the S&P 500.
-
Nursing Home Industry Wants Trump to Rescind Staffing Mandate
A Biden administration rule that imposed minimum rules on nursing levels may not survive, even though many homes lack enough workers to maintain residents’ care.
-
Will the Markets Check Trump’s Power?
The president-elect cares about financial markets, our columnist says. That gives investors a restraint on his decisions, even if it’s a tenuous one.
-
Trump’s Cabinet Picks Having a Familiar, Traditional Look
The Trump cabinet is mostly complete — at least until the official nomination and confirmation process — and it is quite a picture.
-
Drug Companies Face Hostility as They Hope for Allies Among Trump’s Health Picks
Robert F. Kennedy Jr. and other candidates for top health posts are at odds with the drug industry, setting the stage for tense battles over regulatory changes.